DOCSLIB.ORG

6.5 X 11 Double Line.P65

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
6.5 X 11 Double Line.P65 Cambridge University Press 978-0-521-74396-9 - The Prescriber’s Guide, Antidepressants, Third Edition Stephen M. Stahl Index More information Index by Drug Name Abilify (aripiprazole), 17 Azona (trazodone), 215 Acuilix (moclobemide), 137 Belpax (amitriptyline), 1 Adapin (doxepin), 69 Benpon (nortriptyline), 149 Adepil (amitriptyline), 1 Berk-Dothiepin (dothiepin), 63 Adofen (fluoxetine), 89 Besitran (sertraline), 197 Allegron (nortriptyline), 149 Bioxetin (fluoxetine), 89 Alti-Desipramine (desipramine), 49 bupropion, 29 Alti-Doxepin (doxepin), 69 bupropion SR, 29 Alti-Trazodone (trazodone), 215 bupropion XL, 29 Amboneural (selegiline), 189 Celexa (citalopram), 35 Ambo-neural (selegiline), 189 Cidoxepin (doxepin), 69 Amilin (amitriptyline), 1 Cipram (citalopram), 35 Amilit (amitriptyline), 1 Cipramil (citalopram), 35 Amindan (selegiline), 189 citalopram, 35 Amineurin (amitriptyline), 1 clomipramine, 41 Aminuerin retard (amitriptyline), 1 Clopress (clomipramine), 41 Amioxid (amitriptyline), 1 Coaxil (tianeptine), 203 Amitrip (amitriptyline), 1 Cognitiv (selegiline), 189 Amitriptilin (amitriptyline), 1 Concordin (protriptyline), 171 Amitriptylin (amitriptyline), 1 Concordine (protriptyline), 171 amitriptyline, 1 Cosmopril (selegiline), 189 Amitriptylinum (amitriptyline), 1 Cymbalta (duloxetine), 77 Amitrol (amitriptyline), 1 Dalcipran (milnacipran), 125 Amizol (amitriptyline), 1 Daprimen (amitriptyline), 1 amoxapine, 9 Defanyl (amoxapine), 9 Anafranil (clomipramine), 41 Deftan (lofepramine), 113 Anafranil 75 (clomipramine), 41 Delgian (maprotiline), 119 Anafranil Retard (clomipramine), 41 Demolox (amoxapine), 9 Aneural (maprotiline), 119 Depramine (imipramine), 101 Antideprin (imipramine), 101 Deprax (trazodone), 215 Antiparkin (selegiline), 189 Deprenon (fluoxetine), 89 Apo-Amitriptyline (amitriptyline), 1 Deprenyl (selegiline), 189 Apo-Clomipramine (clomipramine), 41 Depressase (maprotiline), 119 Apo-Desipramine (desipramine), 49 Deprex (fluoxetine), 89 Apo-Doxepin (doxepin), 69 Deprilan (selegiline), 189 Apo-Fluoxetine (fluoxetine), 89 Deprilept (maprotiline), 119 Apo-Imipramine (imipramine), 101 Deprimyl (lofepramine), 113 Aponal (doxepin), 69 Deprinol (imipramine), 101 Apo-Selegiline (selegiline), 189 Deptran (doxepin), 69 Apo-Trazodone (trazodone), 215 Deroxat (paroxetine), 157 Apo-Trimip (trimipramine), 221 Desidox (doxepin), 69 Aremis (sertraline), 197 desipramine, 49 Arima (moclobemide), 137 Desitriptylin (amitriptyline), 1 aripiprazole, 17 desvenlafaxine, 57 Arol (moclobemide), 137 Desyrel (trazodone), 215 Aropax (paroxetine), 157 Devidon (trazodone), 215 Asendin (amoxapine), 9 Dinalexin (fluoxetine), 89 Asendis (amoxapine), 9 Dobupal (venlafaxine), 227 atomoxetine, 23 Domical (amitriptyline), 1 Aurorix (moclobemide), 137 Dominans (nortriptyline), 149 Aventyl (nortriptyline), 149 DOM-trazodone (trazodone), 215 Avoxin (fluvoxamine), 95 Doneurin (doxepin), 69 233 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-74396-9 - The Prescriber’s Guide, Antidepressants, Third Edition Stephen M. Stahl Index More information Dopress (dothiepin), 63 Herphonal (trimipramine), 221 Dothep (dothiepin), 63 Hydophen (clomipramine), 41 dothiepin, 63 Idom (dothiepin), 63 Doxal (doxepin), 69 Imavate (imipramine), 101 Doxedyn (doxepin), 69 Imipramiin (imipramine), 101 doxepin, 69 Imipramin (imipramine), 101 duloxetine, 77 imipramine, 101 Dumirox (fluvoxamine), 95 isocarboxazid, 107 Dumyrox (fluvoxamine), 95 Ixel (milnacipran), 125 Dutonin (nefazodone), 143 Janimine (imipramine), 101 Edronax (reboxetine), 183 Jardin (dothiepin), 63 Efectin (venlafaxine), 227 Jatrosom (tranylcypromine), 209 Efexir (venlafaxine), 227 Jatrosom N (tranylcypromine), 209 Efexor (venlafaxine), 227 Julap (selegiline), 189 Efexor XL (venlafaxine), 227 Jumex (selegiline), 189 Effexor (venlafaxine), 227 Jumexal (selegiline), 189 Effexor XR (venlafaxine), 227 Kanopan 75 (maprotiline), 119 Egibren (selegiline), 189 Kinabide (selegiline), 189 Elavil (amitriptyline), 1 Ladose (fluoxetine), 89 Elavil Plus (amitriptyline), 1 Laroxyl (amitriptyline), 1 Eldepryl (selegiline), 189 Lentizol (amitriptyline), 1 Eliwel (amitriptyline), 1 Lexapro (escitalopram), 83 Elopram (citalopram), 35 Lilly Fluoxetine (fluoxetine), 89 Emdalen (lofepramine), 113 lofepramine, 113 Emsam (transdermal selegiline), 189 Lorien (fluoxetine), 89 Endep (amitriptyline), 1 Lovan (fluoxetine), 89 Erocap (fluoxetine), 89 Ludiomil (maprotiline), 119 escitalopram, 83 Lustral (sertraline), 197 Eutimil (paroxetine), 157 Luvox (fluvoxamine), 95 Exostrept (fluoxetine), 89 Maludil (maprotiline), 119 Faverin (fluvoxamine), 95 Manerix (moclobemide), 137 Felicium (fluoxetine), 89 Mapro Gry (maprotiline), 119 Fevarin (fluvoxamine), 95 Mapro Tablinen (maprotiline), 119 Flonital (fluoxetine), 89 Maprolu (maprotiline), 119 Floxyfral (fluvoxamine), 95 Maprolu-50 (maprotiline), 119 Fluctin (fluoxetine), 89 Maprostad (maprotiline), 119 Fluctine (fluoxetine), 89 Maprotibene (maprotiline), 119 Fluocim (fluoxetine), 89 Maprotilin (maprotiline), 119 Fluoxeren (fluoxetine), 89 maprotiline, 119 fluoxetine, 89 Mareen 50 (doxepin), 69 Fluoxifar (fluoxetine), 89 Marplan (isocarboxazid), 107 Fluoxin (fluoxetine), 89 Martimil (nortriptyline), 149 Flutin (fluoxetine), 89 Maveral (fluvoxamine), 95 Fluval (fluoxetine), 89 Maximed (protriptyline), 171 fluvoxamine, 95 Maxivalet (amitriptyline), 1 Fluxadir (fluoxetine), 89 Melipramin (imipramine), 101 Fluxonil (fluoxetine), 89 Melipramine (imipramine), 101 Fondur (fluoxetine), 89 Menfazona (nefazodone), 143 Fontex (fluoxetine), 89 Metylyl (desipramine), 49 Fonzac (fluoxetine), 89 milnacipran, 125 Frosinor (paroxetine), 157 Mipralin (imipramine), 101 Frosnor (paroxetine), 157 Mirpan (maprotiline), 119 Gamanil (lofepramine), 113 mirtazapine, 131 Gamonil (lofepramine), 113 Mocloamine (moclobemide), 137 Gen-Clomipramine (clomipramine), 41 moclobemide, 137 Gladem (sertraline), 197 Molipaxin (trazodone), 215 Harmomed (dothiepin), 63 Motipress (nortriptyline), 149 234 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-74396-9 - The Prescriber’s Guide, Antidepressants, Third Edition Stephen M. Stahl Index More information Motival (nortriptyline), 149 Poldoxin (doxepin), 69 Motivan (paroxetine), 157 Polysal (amitriptyline), 1 Movergan (selegiline), 189 Portal (fluoxetine), 89 Moverin (selegiline), 189 Pragmarel (trazodone), 215 Moxadil (amoxapine), 9 Prisdal (citalopram), 35 Mutan (fluoxetine), 89 Pristiq (desvenlafaxine), 57 Nailin (nortriptyline), 149 Procythol (selegiline), 189 Nalin (nortriptyline), 149 Prothiaden (dothiepin), 63 Nardelzine (phenelzine), 165 Protiaden (dothiepin), 63 Nardil (phenelzine), 165 protriptyline, 171 Nefadar (nefazodone), 143 Prozac (fluoxetine), 89 nefazodone, 143 Prozyn (fluoxetine), 89 Nefirel (nefazodone), 143 Pryleugan (imipramine), 101 Nicoflox (fluoxetine), 89 Psymoin (maprotiline), 119 Nopress (nortriptyline), 149 quetiapine, 177 Norebox (reboxetine), 183 Quitaxon (doxepin), 69 Norfenazin (nortriptyline), 149 reboxetine, 183 Noriline (nortriptyline), 149 Redomex (amitriptyline), 1 Noritren (nortriptyline), 149 RedomexDiffucaps (amitriptyline), 1 Norpramin (desipramine), 49 Regepar (selegiline),189 Northiaden (dothiepin), 63 Remergil (mirtazapine), 131 Nortimil (desipramine), 49 Remeron (mirtazapine), 131 Nortix (nortriptyline), 149 Reneuron (fluoxetine), 89 Nortrilen (nortriptyline), 149 Reseril (nefazodone), 143 Nortriptilin (nortriptyline), 149 Retinyl (maprotiline), 119 nortriptyline, 149 Rexer (mirtazapine), 131 Novo-Clopamine (clomipramine), 41 Rho-Doxepin (doxepin), 69 Novo-Doxepin (doxepin), 69 Rho-Trimine (trimipramine), 221 Novo-fluoxetine (fluoxetine), 89 Rimarix (moclobemide), 137 Novo-Maprotiline (maprotiline), 119 Rulivan (nefazodone), 143 Novoprotect (amitriptyline), 1 Sanzur (fluoxetine), 89 Novo-Selegine (selegiline), 189 Sapilent (trimipramine), 221 Novo-Trazodone (trazodone), 215 Sarafem (fluoxetine), 89 Novo-Trimipramine (trimipramine), 221 Saroten (amitriptyline), 1 Nu-Trazodone (trazodone), 215 Saroten Retard (amitriptyline), 1 Nu-Trimipramine (trimipramine), 221 Sarotex (amitriptyline), 1 Nycoflox (fluoxetine), 89 Sartuzin (fluoxetine), 89 Omnipress (amoxapine), 9 Sedacoroxen (imipramine), 101 Orthon (fluoxetine), 89 Seledat (selegiline), 189 Pamelor (nortriptyline), 149 Selegam (selegiline), 189 Parkinyl (selegiline), 189 selegiline, 189 Parmodalin (tranylcypromine), 209 Selepar (selegiline), 189 Parnate (tranylcypromine), 209 Selepark (selegiline), 189 paroxetine, 157 Seletop 5 (selegiline), 189 paroxetine CR, 157 Selgene (selegiline), 189 Parstelin (tranylcypromine), 209 Selpar (selegiline), 189 Paxil (paroxetine), 157 Sensaval (nortriptyline), 149 Paxil CR (paroxetine CR), 157 Sensival (nortriptyline), 149 Paxtibi (nortriptyline), 149 Sepatrem (selegiline), 189 Pertofrane (desipramine), 49 Serad (sertraline), 197 Pertofrin (desipramine), 49 Serafem (fluoxetine), 89 phenelzine, 165 Seralgan (citalopram), 35 Placil (clomipramine), 41 Sereupin (paroxetine), 157 Plurimen (selegiline), 189 Serlain (sertraline), 197 PMS-Desipramine (desipramine), 49 Serol (fluoxetine), 89 PMS-Fluoxetine (fluoxetine), 89 Seronil (fluoxetine), 89 PMS-Trazodone (trazodone), 215 Seropram (citalopram), 35 235 © Cambridge University Press www.cambridge.org Cambridge University Press 978-0-521-74396-9 - The Prescriber’s Guide, Antidepressants, Third Edition Stephen M. Stahl Index More information Seroquel (quetiapine), 177 Trepiline (amitriptyline), 1 Seroquel XR (quetiapine), 177 Tresleen (sertraline), 197 Seroxal (paroxetine), 157 Trevilor (venlafaxine),
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Of 36 Commentary USP 40–NF 35, First Supplement February 1, 2017
    Commentary USP 40–NF 35, First Supplement February 1, 2017 In accordance with USP’s Rules and Procedures of the Council of Experts (“Rules”) and except as provided in Section 7.02 Accelerated Revision Processes, USP publishes proposed revisions to the United States Pharmacopeia and the National Formulary (USP–NF) for public review and comment in the Pharmacopeial Forum (PF), USP’s free bimonthly journal for public notice and comment. After comments are considered and incorporated as the Expert Committee deems appropriate, the proposal may advance to official status or be re-published in PF for further notice and comment, in accordance with the Rules. In cases when proposals advance to official status without re-publication in PF, a summary of comments received and the appropriate Expert Committee's responses are published in the Revisions and Commentary section of the USP.org at the time the official revision is published. The Commentary is not part of the official text and is not intended to be enforceable by regulatory authorities. Rather, it explains the basis of Expert Committees’ responses to public comments on proposed revisions. If there is a difference between the contents of the Commentary and the official text, the official text prevails. In case of a dispute or question of interpretation, the language of the official text, alone and independent of the Commentary, shall prevail. For further information, contact: USP Executive Secretariat United States Pharmacopeia 12601 Twinbrook Parkway Rockville, MD 20852-1790 USA [email protected]
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Deferrals for USP39-NF34 2S
    Compendial Deferrals for USP39-NF34 2S Category Monograph Title Monograph Section Scientific Liaison Title, Introduction, DEFINITION/Introduction, IDENTIFICATION/A., IDENTIFICATION/B., ASSAY/Procedure, PURITY/Procedure, IMPURITIES/Clostripain Activity/Potassium phosphate buffer, IMPURITIES/Clostripain Activity/Dithiothreitol solution, IMPURITIES/Clostripain Activity/Calcium chloride solution, IMPURITIES/Clostripain Activity/Substrate stock solution, IMPURITIES/Clostripain Activity/Substrate solution, IMPURITIES/Clostripain Activity/Sample solution, IMPURITIES/Clostripain Activity/Instrumental conditions, IMPURITIES/Clostripain Activity/Analysis, IMPURITIES/Clostripain Activity/System suitability, IMPURITIES/Clostripain Activity/Acceptance criteria, IMPURITIES/Trypsin Activity/Buffer, IMPURITIES/Trypsin Activity/Substrate stock solution, IMPURITIES/Trypsin Activity/Substrate solution, IMPURITIES/Trypsin Activity/Sample solution, IMPURITIES/Trypsin Activity/Instrumental conditions, IMPURITIES/Trypsin Activity/Analysis, IMPURITIES/Trypsin Activity/System suitability, IMPURITIES/Trypsin Activity/Acceptance criteria, SPECIFIC TESTS/Protein Content, SPECIFIC TESTS/Bacterial Endotoxins Test <85>, SPECIFIC TESTS/Microbial Enumeration Tests <61>, ADDITIONAL REQUIREMENTS/Packaging and Storage, ADDITIONAL REQUIREMENTS/Labeling, ADDITIONAL REQUIREMENTS/USP New <89.1> COLLAGENASE I PF 41(5) Pg. ONLINE Reference Standards <11> Edith Chang Title, Introduction, DEFINITION/Introduction, IDENTIFICATION/A., IDENTIFICATION/B., ASSAY/Procedure, PURITY/Procedure,
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr
    US008158152B2 (12) United States Patent (10) Patent No.: US 8,158,152 B2 Palepu (45) Date of Patent: Apr. 17, 2012 (54) LYOPHILIZATION PROCESS AND 6,884,422 B1 4/2005 Liu et al. PRODUCTS OBTANED THEREBY 6,900, 184 B2 5/2005 Cohen et al. 2002fOO 10357 A1 1/2002 Stogniew etal. 2002/009 1270 A1 7, 2002 Wu et al. (75) Inventor: Nageswara R. Palepu. Mill Creek, WA 2002/0143038 A1 10/2002 Bandyopadhyay et al. (US) 2002fO155097 A1 10, 2002 Te 2003, OO68416 A1 4/2003 Burgess et al. 2003/0077321 A1 4/2003 Kiel et al. (73) Assignee: SciDose LLC, Amherst, MA (US) 2003, OO82236 A1 5/2003 Mathiowitz et al. 2003/0096378 A1 5/2003 Qiu et al. (*) Notice: Subject to any disclaimer, the term of this 2003/OO96797 A1 5/2003 Stogniew et al. patent is extended or adjusted under 35 2003.01.1331.6 A1 6/2003 Kaisheva et al. U.S.C. 154(b) by 1560 days. 2003. O191157 A1 10, 2003 Doen 2003/0202978 A1 10, 2003 Maa et al. 2003/0211042 A1 11/2003 Evans (21) Appl. No.: 11/282,507 2003/0229027 A1 12/2003 Eissens et al. 2004.0005351 A1 1/2004 Kwon (22) Filed: Nov. 18, 2005 2004/0042971 A1 3/2004 Truong-Le et al. 2004/0042972 A1 3/2004 Truong-Le et al. (65) Prior Publication Data 2004.0043042 A1 3/2004 Johnson et al. 2004/OO57927 A1 3/2004 Warne et al. US 2007/O116729 A1 May 24, 2007 2004, OO63792 A1 4/2004 Khera et al.
    [Show full text]
  • WO 2007/061529 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date (10) International Publication Number 31 May 2007 (31.05.2007) PCT WO 2007/061529 Al (51) International Patent Classification: GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, A61K 9/14 (2006.01) KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, MZ, (21) International Application Number: NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, PCT/US2006/040197 SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (22) International Filing Date: 13 October 2006 (13.10.2006) (84) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (26) Publication Language: English ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV,MC, NL, PL, PT, (30) Priority Data: RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, 11/282,507 18 November 2005 (18.1 1.2005) US GN, GQ, GW, ML, MR, NE, SN, TD, TG). (71) Applicant (for all designated States except US): SCI- Declarations under Rule 4.17: DOSE PHARMA INC.
    [Show full text]
  • International Journal of Pharmacy & Life Sciences
    Research Article [Vukkum et al., 5(11): Nov., 2014:3986-4006] CODEN (USA): IJPLCP ISSN: 0976-7126 INTERNATIONAL JOURNAL OF PHARMACY & LIFE SCIENCES (Int. J. of Pharm. Life Sci.) Isolation and structural characterization of Imipramine hydrochloride degradation impurities and development of stability-indicating UPLC method Pallavi Vukkum1*, J. Moses Babu1 and R. Muralikrishna2 1, Analytical Research, Custom Pharmaceutical Services, Dr. Reddy’s Laboratories, Hyderabad - India 2, Department of Chemistry, Andhra University, Visakhapatnam - India Abstract A novel, high-throughput, reverse phase-ultra performance liquid chromatographic (RP-UPLC) method has been developed for the quantification of Imipramine and its related impurities in drug substance. The stability-indicating capability of the developed method is demonstrated using forced degradation samples from stress conditions such as hydrolysis, oxidation, thermal and photolytic degradation. During forced degradation it has been observed significant degradation of drug substance in acid hydrolysis and oxidative conditions. Two of the major degradation impurities are isolated using semi preparative HPLC, and the structures are elucidated using 1HNMR, 13CNMR, 2D NMR (COESY, HSQC, HMBC) and mass spectral data. Based on the complete spectral analysis, these two degradation impurities are designated as 10-(3-(dimethylamino)propyl)acridin-9(10H)-one (acid hydrolysis) and 3- (10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amineoxide (oxidative degradation). The separation of known impurities and degradation impurities are accomplished using a YMC TriArt C18 stationary phase with 100 mm length and 1.9 µm particle size in short run time (10 min). The developed method employs a linear gradient elution with ammonium acetate buffer, and mixture of acetonitrile and methanol as mobile phase, and is validated in accordance with International Conference on Harmonization requirements.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]